Epigenetics of pituitary tumors: Pathogenetic and therapeutic implications

Shereen Ezzat; Sonia Cheng; Sylvia L Asa

doi:10.1016/j.mce.2017.07.011

Epigenetics of pituitary tumors: Pathogenetic and therapeutic implications

Mol Cell Endocrinol. 2018 Jul 5:469:70-76. doi: 10.1016/j.mce.2017.07.011. Epub 2017 Jul 12.

Authors

Shereen Ezzat¹, Sonia Cheng², Sylvia L Asa³

Affiliations

¹ Department of Medicine, University of Toronto, The Endocrine Oncology Site Group, Princess Margaret Cancer Centre, and The Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada. Electronic address: shereen.ezzat@utoronto.ca.
² Department of Medicine, University of Toronto, The Endocrine Oncology Site Group, Princess Margaret Cancer Centre, and The Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada.
³ Department of Laboratory Medicine & Pathobiology, University of Toronto, The Endocrine Oncology Site Group, Princess Margaret Cancer Centre, and The Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada.

PMID: 28711607
DOI: 10.1016/j.mce.2017.07.011

Abstract

Genetic mutations involving oncogenes or tumor suppressor genes are relatively uncommon in human sporadic pituitary tumors. Instead, increasing evidence has highlighted frequent epigenetic alterations including DNA methylation, histone modifications, and enhanced miRNA expression. This review covers some of this evidence as it illuminates mechanisms of tumorigenesis and highlights therapeutic opportunities.

Keywords: DNA methylation; Histone modification; Ikaros; MAGE; miRNA.

Publication types

Review

MeSH terms

Animals
Chromatin Assembly and Disassembly / genetics
DNA Methylation / genetics
Epigenesis, Genetic*
Histones / metabolism
Humans
Pituitary Neoplasms / genetics
Pituitary Neoplasms / pathology*
Pituitary Neoplasms / therapy*
Protein Processing, Post-Translational / genetics

Substances

Histones